Shares of Uniqure NV (NASDAQ:QURE) have been given an average rating of “Buy” by the thirteen brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $74.00.
A number of analysts recently issued reports on QURE shares. B. Riley started coverage on Uniqure in a report on Monday, December 31st. They issued a “buy” rating and a $72.00 price target for the company. Guggenheim started coverage on Uniqure in a report on Monday, December 17th. They issued a “buy” rating and a $35.00 price target for the company. HC Wainwright set a $60.00 price target on Uniqure and gave the company a “buy” rating in a report on Tuesday, December 4th. Chardan Capital reiterated a “buy” rating and issued a $70.00 price target on shares of Uniqure in a report on Monday, December 3rd. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $68.00 price target on shares of Uniqure in a report on Friday, February 8th.
In other Uniqure news, SVP Alexander Edward Kuta III sold 1,052 shares of the company’s stock in a transaction on Monday, January 28th. The stock was sold at an average price of $31.29, for a total transaction of $32,917.08. Following the completion of the sale, the senior vice president now owns 26,578 shares in the company, valued at $831,625.62. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 67,376 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $63.96, for a total value of $4,309,368.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 113,390 shares of company stock valued at $5,764,148. 1.56% of the stock is owned by company insiders.
Shares of QURE traded down $0.20 during mid-day trading on Friday, reaching $63.35. 592,006 shares of the company’s stock traded hands, compared to its average volume of 534,900. The stock has a market cap of $2.44 billion, a price-to-earnings ratio of -27.07 and a beta of 1.07. Uniqure has a 12 month low of $20.29 and a 12 month high of $67.93. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.85 and a current ratio of 11.85.
Uniqure (NASDAQ:QURE) last released its earnings results on Thursday, February 28th. The biotechnology company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.08. Uniqure had a negative return on equity of 47.73% and a negative net margin of 738.25%. As a group, analysts predict that Uniqure will post -2.8 earnings per share for the current fiscal year.
Uniqure Company Profile
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.
Featured Article: How are institutional investors different from individual investors?
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.